sofosbuvir

Gilead hepatitis C drug patent faces European challenge
Yahoo/Reuters
Mon, 03/27/17 - 09:47 am
Gilead Sciences
hepatitis C
Europe
sofosbuvir
Gilead May Have to Pay Rival Merck Billions in Royalties
Fortune
Wed, 03/23/16 - 04:04 pm
Gilead Sciences
Merck
patents
sofosbuvir
Harvoni
Sovaldi
hepatitis C
Merck wins major victory in hep C patent case against Gilead
BioPharma Dive
Wed, 03/23/16 - 09:45 am
Merck
hepatitis C
patents
Gilead Sciences
sofosbuvir
Harvoni
Sovaldi
The Price Keeps Falling For a Superstar Gilead Drug in India
Bloomberg
Tue, 12/29/15 - 09:33 am
India
Gilead Sciences
sofosbuvir
Sovaldi
hepatitis C
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
Yahoo
Wed, 05/20/15 - 10:20 am
Bristol-Myers Squibb
FDA
breakthrough therapies
daclatasvir
hepatitis C
sofosbuvir
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
Yahoo/BusinessWire
Sat, 11/8/14 - 11:35 am
daclatasvir
sofosbuvir
hepatitis C
hepatitis
Bristol-Myers Squibb
Gilead says Japanese hepatitis C trial meets goal
Yahoo/Reuters
Wed, 04/2/14 - 10:01 pm
Gilead Sciences
Japan
hepatitis C
sofosbuvir
Gilead Wins FDA Approval for Blockbuster Hepatitis C Pill
Bloomberg
Fri, 12/6/13 - 05:41 pm
sofosbuvir
FDA
Gilead Science
hepatitis C
Sovaldi
What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs
Seeking Alpha
Fri, 12/6/13 - 10:30 am
JNJ
Gilead Sciences
hepatitis C
sofosbuvir
Olysio
AbbVie
Bristol-Myers Squibb
Merck
3 Biopharmas Hoping for Good News From the FDA
Motley Fool
Wed, 12/4/13 - 03:45 pm
FDA
Auxilium
Xiaflex
Gilead
sofosbuvir
GSK
Theravance
Anoro Ellipta
Idenix fires off a shot in patent battle over Gilead's sofosbuvir
Fierce Biotech
Mon, 12/2/13 - 05:04 pm
Idenix
Gilead
sofosbuvir
hepatitis C
Four Biotech 'Surprise' Stocks for 2014
TheStreet.com
Wed, 11/27/13 - 08:34 am
Seattle Genetics
Adcetris
Cubist Pharmaceuticals
Cempra
Eylea
Regeneron
Pharmacyclics
Imbruvica
Gilead
sofosbuvir
3 Can't-Miss FDA Actions Coming in December
Motley Fool
Tue, 11/26/13 - 04:42 pm
FDA
Gilead Sciences
sofosbuvir
Forxiga
AstraZeneca
Bristol-Myers Squibb
GSK
Anoro Ellipta
Theravance
New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014
Seeking Alpha
Tue, 11/26/13 - 04:37 pm
hepatitis C
Gilead Sciences
sofosbuvir
4 Biotech Stocks With Upcoming FDA Decision Dates
Seeking Alpha
Mon, 11/25/13 - 10:22 am
FDA
Gilead
Auxilium
GSK
Theravance
sofosbuvir
Xiaflex
Anoro
Gilead And AbbVie Battle For Top Spot In $20 Billion Hepatitis Drug Market
Seeking Alpha
Sun, 11/24/13 - 12:24 pm
Gilead Sciences
AbbVie
hepatitis
hepatitis C
sofosbuvir
ABT-450
ABT-333
ABT-267
AbbVie steps closer to FDA filing as first hep C PhIII delivers promising results
Fierce Biotech
Mon, 11/18/13 - 10:04 am
sofosbuvir
FDA
AbbVie
hepatitis C
How Much? A Battle Over The Cost Of The New Hepatitis C Drugs
Pharmalot
Mon, 11/11/13 - 11:40 am
hepatitis C
drug pricing
sofosbuvir
FDA
Gilead Sciences
Gilead Vs. Challengers In The Hepatitis C Race
Seeking Alpha
Thu, 11/7/13 - 09:52 am
Gilead
hepatitis C
AbbVie
Bristol-Myers Squibb
JNJ
Merck
simeprevir
sofosbuvir
daclatasvir
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
Yahoo/BusinessWire
Sat, 11/2/13 - 11:28 am
Gilead
hepatitis C
sofosbuvir

Pages